AVBCC Leadership & Co-Chairs | Value-Based Cancer Care

Featured Content

Navigating Care Programs in the Post-OCM era

Since OCM ended in June of 2022, oncology practice leaders have navigated complex decisions about how to offer patients high-quality, value-driven cancer care and in which reimbursement programs they will participate.

View Content
The Future of Cancer Care Delivery

The future of cancer care delivery is shifting from fee-for-service to a value-based care approach.

View Content
Research Indicates Fewer People Understand the Link Between HPV and Certain Cancers

Vaccination against human papillomavirus (HPV) can prevent several types of cancer, including cervical, oral/oropharyngeal, penile, and anal cancers.

View Content
Listen to our AVBCC Podcasts

Now you can take the Association for Value-Based Cancer Care (AVBCC) on the go with AVBCC podcasts. As healthcare professionals, it can be hard to find time in your busy schedule to stay up-to-date on oncology trends. Now you can receive trusted information from top industry leaders in an easy-to-listen format.

View Content

Top Trending Articles

1.

Navigating the Complex Landscape of Oral Cancer Medication

2.

Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS

3.

New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors

FDA Approvals, News & Updates

Fruzaqla FDA Approved for Relapsed Metastatic Colorectal Cancer

FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Metastatic or Recurrent Nasopharyngeal Carcinoma

Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of GEJ Adenocarcinoma

View More Articles

Highlights from the Latest Issue: December 2023, Vol 14, No 6

December 2023, Vol 14, No 6

Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC

By William King

Fruzaqla FDA Approved for Relapsed Metastatic Colorectal Cancer

AVBCC Keynote: The Path to Innovation in Oncology

By Phoebe Starr

FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Metastatic or Recurrent Nasopharyngeal Carcinoma

Value-Based Care

Survey Shows Inflation Affecting Majority of Consumer Healthcare Decisions

Breast Reconstruction Disparities Improve Significantly with Medicaid Expansion

Walter Alexander

Innovative Technology Supports Value-Based Care Success

Amy Valley, PharmD

The Alliance for Innovation in Integrated Healthcare Provides New Forum for Stakeholders

View More Articles

Personalized Medicine | Browse By Specialty

Hematologic Malignancies

Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS

Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa.

Quick Quiz: Chronic Myeloid Leukemia

Quick Quiz: Chronic Myeloid Leukemia

Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is a malignancy that originates in blood-forming cells (called myeloid cells) found in bone marrow. How much do you know about chronic myeloid leukemia?

Cheryl Allen, MBA

Cheryl Ann Allen, MBA, BS Pharm

Founding Partner
Curatio Scientia Advisors

Natalie Bedford

Natalie Bedford

Senior VP
CenterWell Specialty Pharmacy
(Humana Specialty Pharmacy)

Sibel Blau

Sibel Blau, MD

President & CEO
QCCA, LLC
Medical Director
Northwest Medical Specialties, PLLC

Mark Chassay

Mark Chassay, MD, MEd, MBA

Chief Medical Officer
Blue Cross and Blue Shield of Texas

Blair Childs

Blair Childs

Senior Executive Advisor
Premier, Inc.

Caleb DesRosiers, JD, MPA

Caleb DesRosiers, JD, MPA

Commercial Operations & Policy Executive
COPILOT

John Fox, MD, MHA

Medical Director
Managed Care, OneOncology

Marianne Gandee

Marianne Gandee

Vice President
Patient Solutions & Alliances, North America
Pfizer Oncology

Stephen Grubbs

Stephen Grubbs, MD, FASCO

Vice President
Care Delivery
American Society of Clinical Oncology

Beth Hamilton

Beth Hamilton, MBA

Vice President
Global Oncology Market
Access and Pricing
AstraZeneca

Lisa Harrison

Lisa Harrison, RPh

President and General Manager
Oncology Supply
AmerisourceBergen

Ross Hoffman

Ross Hoffman, MD

Medical Director
Centene

Michael Kolodziej

Michael Kolodziej, MD

Senior Advisor
ADVI Health

Lucy Ruwitch Langer

Lucy Ruwitch Langer, MS, MD

National Medical Director
Oncology and Genomics
UnitedHealthcare

Doug Long

Doug Long

Vice President
Industry Relations
IQVIA

William McGivney

William McGivney, PhD

Managing Principal
McGivney Global Advisors

Kathy Oubre, MS

Chief Executive Officer
Pontchartrain Cancer Center

Alti Rahman

Alti Rahman, MHA, MBA, CSSBB

Chief Strategy and Innovation Officer
American Oncology Network, LLC (AON)

Chevon Rariy

Chevon Rariy, MD

Venture Partners
Takeda Digital Ventures

Marc Samuels

Marc Samuels

Founder & CEO
ADVI Health

Jayson Slotnik

Jayson Slotnik, JD, MPH

Partner
Health Policy Strategies

Lalan Wilfong

Lalan Wilfong, MD

VP Payer Relations and Practice Transformation
The US Oncology Network

Burt Zweigenhaft

Burt Zweigenhaft, PhD, DLitt

Executive Director and Co-founder
Association for Value-Based Cancer Care

Latest Videos

Managing Cost and Patient Risk for Optimal Value-Bases Care

Managing Cost and Patient Risk for Optimal Value-Bases Care

Bringing Stakeholders Together Bringing Stakeholders Together

Bringing Stakeholders Together Bringing Stakeholders Together

View More Videos

We Want to Know